QQQ $ 617.97 $ 1.98 (0.32 %)
DIA $ 472.85 $ 2.95 (0.63 %)
SPY $ 678.10 $ 1.62 (0.24 %)
TLT $ 91.54 $ -0.02 (-0.02 %)
GLD $ 379.15 $ 0.60 (0.16 %)
$ 7.02
-- x --
-- x --
-- - --
$ 3.08 - $ 9.67
4,585,688
na
572.73M
$ 1.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 01-10-2025 11-30-2024 10-Q
2 10-08-2024 08-31-2024 10-Q
3 06-27-2024 05-31-2024 10-Q
4 04-25-2024 02-29-2024 10-K
5 01-08-2024 11-30-2023 10-Q
6 10-04-2023 08-31-2023 10-Q
7 06-29-2023 05-31-2023 10-Q
8 04-28-2023 02-28-2023 10-K
9 01-09-2023 11-30-2022 10-Q
10 10-06-2022 08-31-2022 10-Q
11 07-01-2022 05-31-2022 10-Q
12 05-02-2022 02-28-2022 10-K
13 01-11-2022 11-30-2021 10-Q
14 10-07-2021 08-31-2021 10-Q
15 07-08-2021 05-31-2021 10-Q
16 05-07-2021 02-28-2021 10-K
17 01-07-2021 11-30-2020 10-Q
18 10-14-2020 08-31-2020 10-Q
19 08-13-2020 05-31-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 accolade-announces-that-stockholders-voted-to-approve-merger-with-transcarent

Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade specia...

 cathie-woods-ark-invest-loads-up-on-tempus-ai-archer-aviation-but-sells-twist-bioscience-here-are-key-ark-trades-this-friday

Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TW...

 stephens--co-reiterates-equal-weight-on-accolade-maintains-703-price-target

Stephens & Co. analyst Jeff Garro reiterates Accolade (NASDAQ:ACCD) with a Equal-Weight and maintains $7.03 price target.

 cathie-woods-ark-invest-bets-big-on-amazon-roblox-and-illumina-while-trimming-palantir-stake-after-alex-karp-led-company-touched-an-all-time-high-on-thursday

Ark Invest made significant trades on Friday, including buying Amazon and Roblox stock and selling Palantir stock. Other key tr...

 cathie-woods-ark-invest-bets-on-biotech-with-crispr-therapeutics-investment-exits-roblox

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.

 cathie-woods-wednesday-moves-ark-invest-dumps-robinhood-stock

On Wednesday January 22, 2025, Cathie Wood-led Ark Invest sold $927,107 worth of Robinhood shares.

 cathie-woods-ark-invest-buys-into-defense-and-energy-stocks-amid-trumps-inaugural-policies

Cathie Wood-led Ark Invest made significant trades involving ACCD, DE, NTLA, PATH, CCJ, OKLO, ILMN, ESLT, and ABSI.

 cathie-woods-ark-invest-is-betting-big-on-this-ai-darling-and-no-its-not-nvidia

Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG...

 accolade-q3-earnings-assessment
Accolade Q3 Earnings Assessment
01/10/2025 21:35:07

 stifel-downgrades-accolade-to-hold-lowers-price-target-to-703

Stifel analyst David Grossman downgrades Accolade (NASDAQ:ACCD) from Buy to Hold and lowers the price target from $8 to $7.03.

 raymond-james-downgrades-accolade-to-market-perform

Raymond James analyst John Ransom downgrades Accolade (NASDAQ:ACCD) from Outperform to Market Perform.

 needham-downgrades-accolade-to-hold

Needham analyst Ryan MacDonald downgrades Accolade (NASDAQ:ACCD) from Buy to Hold.

 canaccord-genuity-downgrades-accolade-to-hold

Canaccord Genuity analyst Richard Close downgrades Accolade (NASDAQ:ACCD) from Buy to Hold.

 why-is-accolade-stock-trading-over-100-on-tuesday

Transcarent to acquire Accolade Inc. for $7.03 per share, combining AI-driven care solutions with personalized healthcare exper...

 whats-going-on-with-accolade-stock-wednesday

Accolade shares are trading higher on Wednesday after it announced that Transcarent will acquire the company.

 leerink-partners-downgrades-accolade-to-market-perform

Leerink Partners analyst Michael Cherny downgrades Accolade (NASDAQ:ACCD) from Outperform to Market Perform.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION